The majority of fatal cases of malaria are caused by infection with the parasite Plasmodium falciparum. Most at risk are young children and women who are pregnant. A team of researchers, led by Patrick Duffy, at the National Institutes of Health, Rockville, has now developed an approach to profile P. falciparum parasites in such a way that they are able to identify parasite genes associated with severe infection.
In the study, they identified a distinct subset of genes in parasites infecting pregnant women, including a gene whose protein product is already known to be important for severe disease in these at risk patients and is a well-established pregnancy malaria vaccine candidate. They also identified a subset of genes that distinguished parasites infecting children from those infecting pregnant women. The team hopes that this information will provide new understanding of the nature of severe childhood malaria. Future experiments will attempt to validate the protein products of these genes as biomarkers of disease severity and targets for new intervention strategies.
Reference: Duffy P. NSR-seq transcriptional profiling enables identification of a gene signature of Plasmodium falciparum parasites infecting children. Journal of Clinical Investigation.
Hiding in Plain Sight: The Most Harmful and Costly Hospital-Acquired Infection
February 5th 2025Nonventilator hospital-acquired pneumonia (NV-HAP) is a deadly, overlooked infection impacting patient outcomes. With new diagnostic tools and prevention strategies, hospitals must prioritize oral hygiene to reduce risk.
Gag Order Puts Public Health at Risk, APIC Urges Immediate Action
February 4th 2025APIC warns that the HHS gag order on CDC communications endangers public health, delaying critical infection updates and weakening outbreak response amid rising tuberculosis, avian flu, Ebola, and measles threats.
Breaking Barriers: The Future of HIV Prevention and the Fight for Widespread PrEP Access
January 31st 2025Despite medical advances, HIV prevention faces roadblocks—low PrEP adoption, stigma, and accessibility issues threaten progress. Experts push for innovative, long-acting solutions to end the epidemic.